In 2025, fertility services continued to see robust M&A and strategic investment activity. A standout example is US Fertility’s strategic partnership with L Catterton and Amulet Capital Partners, a transaction that underscores the maturation and scale potential of fertility care platforms in the broader healthcare ecosystem.
US Fertility, the nation’s leading physician-owned fertility services platform, announced a new strategic partnership with L Catterton, the largest global consumer-focused private equity firm, alongside Amulet Capital Partners, its longtime healthcare-focused private equity backer. Under the revised ownership structure, L Catterton and Amulet will serve as co-lead investors, while US Fertility’s physician partners continue to hold meaningful ownership. The transaction will be financed through a $825 million first-lien term loan B due in 2032 and $1.71 billion of new cash and rollover equity (source).
This deal amplifies US Fertility’s capacity to accelerate access to advanced reproductive technologies, including in-vitro fertilization (IVF), intrauterine insemination (IUI), genetic testing, cryogenic services, and ancillary patient support. It also reinforces a broader market trend: fertility care continues to attract significant investment activity because of its resilient demand, recurring revenue characteristics, and expanding payer participation. As patients increasingly seek personalized and technology-enabled care, platforms like US Fertility are well-positioned to consolidate fragmented services and drive improved outcomes at scale.
For Amboy Street Ventures, tracking deals like US Fertility’s partnership and the broader context in which strategic capital is reshaping care delivery is critical to understanding where women’s health investment momentum is strongest. As the market continues to grow, we expect to see more strategic partnerships, roll-ups, and capital infusions that unlock better access, better outcomes, and better economics for both patients and investors.
Some early-stage players in the fertility care space include:
Bea Fertility (Amboy Street portfolio company; Series A) — Fertility treatment at home, guided by specialists, powered by FDA-cleared insemination devices.
Juniper Genomics (Amboy Street portfolio company; Seed) — Whole-genome sequencing of embryos to improve transfer success.
Conceivable Lifesciences (Series B) — The world’s first AI-powered automated IVF lab.
Sama Fertility (Series A) — World-class fertility care, from anywhere. The highest standards in evidence-backed fertility care, with the convenience of virtual visits and guided at-home monitoring.
